These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 20649825)
1. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. Tanaka Y; Masumori N; Tsukamoto T Int J Urol; 2010 Sep; 17(9):796-800. PubMed ID: 20649825 [TBL] [Abstract][Full Text] [Related]
2. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. Ronchi P; Gravina GL; Galatioto GP; Costa AM; Martella O; Vicentini C Neurourol Urodyn; 2009; 28(1):52-7. PubMed ID: 18671288 [TBL] [Abstract][Full Text] [Related]
3. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies. Capo' JP; Lucente V; Forero-Schwanhaeuser S; He W Postgrad Med; 2011 Jan; 123(1):94-104. PubMed ID: 21293089 [TBL] [Abstract][Full Text] [Related]
5. Prospective open label study of solifenacin for overactive bladder in children. Bolduc S; Moore K; Nadeau G; Lebel S; Lamontagne P; Hamel M J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124 [TBL] [Abstract][Full Text] [Related]
6. [Treatment with solifenacin reduces urinary urgency and improves quality of life. Results of the non-interventional CAP-study]. Kalchthaler M; Mühlich S; Rothe P MMW Fortschr Med; 2011 Jan; 152 Suppl 4():119-24. PubMed ID: 21598462 [No Abstract] [Full Text] [Related]
7. [Treatment of overactive urinary bladder with imperative urinary incontinence in women]. Neĭmark AI; Riapolova MV; Mel'nik MA Urologiia; 2010; (2):36-8. PubMed ID: 20967993 [TBL] [Abstract][Full Text] [Related]
8. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Liu HT; Lin H; Kuo HC Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717 [TBL] [Abstract][Full Text] [Related]
9. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Garely AD; Lucente V; Vapnek J; Smith N Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study. Chung JH; Lee JY; Kang DH; Ha US; Lee SH; Ham WS; Cho KS; Han JH; Park J; Yoo TK; Lee SW Neurourol Urodyn; 2012 Sep; 31(7):1175-80. PubMed ID: 22674356 [TBL] [Abstract][Full Text] [Related]
11. [Solifenacin in treatment of the overactive bladder syndrome--diagnosis, clinical management and results]. Slavov Ch; Popov E; Slavov S; Dimitrov R; Doganov N; Chernev T Akush Ginekol (Sofiia); 2010; 49(3):16-21. PubMed ID: 20734651 [TBL] [Abstract][Full Text] [Related]
12. [Overactive bladder. When it's pressing, immediate help is indicated]. Widhalm S MMW Fortschr Med; 2008 May; 150(20):44-5. PubMed ID: 18605642 [No Abstract] [Full Text] [Related]
13. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M; BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143 [TBL] [Abstract][Full Text] [Related]
14. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. Yamaguchi O; Kakizaki H; Homma Y; Takeda M; Nishizawa O; Gotoh M; Yokoyama O; Seki N; Yoshida M; Urology; 2011 Jul; 78(1):126-33. PubMed ID: 21601248 [TBL] [Abstract][Full Text] [Related]
15. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J; BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Yokoyama O; Yamaguchi O; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M; Yamada S J Urol; 2011 Jul; 186(1):170-4. PubMed ID: 21575976 [TBL] [Abstract][Full Text] [Related]
17. Solifenacin. Kreder KJ Urol Clin North Am; 2006 Nov; 33(4):483-90, ix. PubMed ID: 17011384 [TBL] [Abstract][Full Text] [Related]
18. Solifenacin succinate for the treatment of symptoms of overactive bladder. Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299 [TBL] [Abstract][Full Text] [Related]
19. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887 [TBL] [Abstract][Full Text] [Related]
20. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Kaplan SA; Goldfischer ER; Steers WD; Gittelman M; Andoh M; Forero-Schwanhaeuser S Aging Male; 2010 Jun; 13(2):100-7. PubMed ID: 20001469 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]